Apellis Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Apellis Pharmaceuticals's estimated annual revenue is currently $7.4M per year.
- Apellis Pharmaceuticals received $60.0M in venture funding in August 2017.
- Apellis Pharmaceuticals's estimated revenue per employee is $36,293
- Apellis Pharmaceuticals's total funding is $163.3M.
- Apellis Pharmaceuticals has 205 Employees.
- Apellis Pharmaceuticals grew their employee count by 138% last year.
- Apellis Pharmaceuticals currently has 38 job openings.
|Cedric Francois||Co-founder & CEO/President|
|Pascal Deschatelets||Chief Operating Officer|
|David Watson||General Counsel and Vice President of Corporate Development|
|Federico Grossi||Chief Medical Officer|
|Derek Wachtel||Associate Director, DMPK|
|Kristopher Weatherby||Associate Director, Technical Operations|
|Mark DeLong||VP, Business Development & Strategy|
|Frank Stout||Director Clinical Operations|
|Adam Townsend||Chief Commercial Officer|
|Stacey Hollon||HR Director|
What Is Apellis Pharmaceuticals?
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Apellis Pharmaceuticals News
WALTHAM, Mass. and CRESTWOOD, Ky., Aug. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (APLS) a clinical-stage ...
CRESTWOOD, Ky. and WALTHAM Mass., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage ...
Alps Advisors Inc. cut its holdings in Apellis Pharmaceuticals Inc (NASDAQ:APLS) by 2.6% during the 2nd quarter, according to the company in ...
Apellis Pharmaceuticals Funding
|2016-02-15||$47.0M||D||Cormorant Asset Management||Article|
|2017-08-11||$60.0M||E||Sectoral Asset Management||Article|
Apellis Pharmaceuticals Executive Hires
|2016-08-09||Robert Kim||Chief Medical Officer||Article|
|2018-11-21||Adam Townsend||Chief Commercial Officer||Article|
|2019-02-01||Thomas Lackner||SVP/Head of Europe||Article|
Apellis Pharmaceuticals Acquisitions
|2014-11-21||Potentia Pharmaceuticals, Inc||Article|